Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.5 HKD | +7.31% | -7.30% | +12.44% |
Sales 2023 | 126M 17.42M 136M | Sales 2024 * | 691M 95.62M 748M | Capitalization | 6.49B 898M 7.02B |
---|---|---|---|---|---|
Net income 2023 | -844M -117M -914M | Net income 2024 * | -724M -100M -784M | EV / Sales 2023 | 48.3 x |
Net cash position 2023 * | 1.06B 147M 1.15B | Net cash position 2024 * | 1.05B 145M 1.13B | EV / Sales 2024 * | 7.87 x |
P/E ratio 2023 * |
-6.71
x | P/E ratio 2024 * |
-8.55
x | Employees | 395 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.91% |
Latest transcript on Everest Medicines Limited
1 day | +7.31% | ||
1 week | -6.37% | ||
Current month | -2.69% | ||
1 month | +8.80% | ||
3 months | +13.53% | ||
6 months | -3.89% | ||
Current year | +12.44% |
Managers | Title | Age | Since |
---|---|---|---|
Yong Qing Luo
CEO | Chief Executive Officer | 54 | 22-09-18 |
Ian Ying Woo
PSD | President | 51 | 18-11-30 |
Michael Berry
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-06-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yi Fan Li
BRD | Director/Board Member | 55 | 20-08-31 |
Honggang Feng
BRD | Director/Board Member | 59 | Feb. 08 |
Wei Fu
CHM | Chairman | 42 | 17-06-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.75% | 4 M€ | -27.92% | ||
0.01% | 4 M€ | -4.41% | - | |
0.00% | 115 M€ | +4.54% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 23.5 | +7.31% | 6 616 000 |
24-03-27 | 21.9 | +1.62% | 5,147,000 |
24-03-26 | 21.55 | -2.93% | 8,697,500 |
24-03-25 | 22.2 | -9.02% | 8,656,049 |
24-03-22 | 24.4 | -2.79% | 4,003,164 |
Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.44% | 898M | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.30% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |